1. Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38.
2. Xi Z, Qing Z, Kun S, Baoxia C, Jie J, Youzhong Z, et al. Five-year survival rate of postoperative ovarian cancer patients: a 15-year retrospective study. 现代妇产科进展. 2017;12:26.
3. Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975–2015. Bethesda: National Cancer Institute; 2018.
4. Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen L-M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer: NCCN.org 2015. 2015. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 22 Juni 2015
5. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–87.